Cancer Trials Ireland — Sponsor Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

1 Recruiting

9 Completed trials

4 Countries active

28 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III: 6 Phase II/III: 2 Phase II: 2 Other: 1

Oversight events:

1 serious breach 4 temporary halts across 3 trials

View oversight register →

100%

9 of 9 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Prostate cancer 3 Squamous cell carcinoma 1

Top IMPs

PACLITAXEL 3 ANASTROZOLE 2 BICALUTAMIDE 2 CISPLATIN 2 DOCETAXEL 2 ENZALUTAMIDE 2 FLUTAMIDE 2 BORTEZOMIB 1 CARBOPLATIN 1 CYCLOPHOSPHAMIDE 1 DAROLUTAMIDE 1 DEXAMETHASONE 1

All trials

11 total

Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positiv… Recruiting

2024-516582-36-00 Phase II/III 1 country PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB DERUXTECAN
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II… Ended

2024-516530-36-00 Phase III 1 country ANASTROZOLE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EXEMESTANE; LETROZOLE; PACLITAXE…
PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory Pancreatic cancer … Ended

2024-513429-21-00 Phase II 1 country HYDROXYCHLOROQUINE SULFATE; TRAMETINIB
Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuxima… Ended

2024-512749-18-00 Phase II 2 countries BORTEZOMIB; DEXAMETHASONE; ISATUXIMAB; LENALIDOMIDE
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 dou… Ended

2024-514565-18-00 Phase III 1 country DAROLUTAMIDE
S1404: A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizuma… Ended

2024-516881-12-00 Phase III 1 country PEMBROLIZUMAB
Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET Ended

2024-516137-13-00 Phase III 1 country BICALUTAMIDE; ENZALUTAMIDE; FLUTAMIDE
SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotheraphy in Patients with 1-3 Positive N… Ended

2024-516801-22-00 Phase III 1 country ANASTROZOLE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN HYDROCHLORIDE; EPIRUBICIN …
A clinical research study comparing two cisplatin dosing schedules combined with radiation for patients with advanced head and neck cancer. Halted

2024-515237-15-00 Phase II/III 1 country CISPLATIN
Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma. … Ended

2024-516945-37-00 1 country
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostat… Ended

2024-514808-13-00 Phase III 3 countries BICALUTAMIDE; ENZALUTAMIDE; FLUTAMIDE; NILUTAMIDE

Showing 1–11 of 11 trials

← All sponsors A–Z